Loading field map
Global health governance is the study and practice of how states, international organizations, non-governmental actors, and private entities collectively manage health issues that cross national borders. It concerns not only the formal rules and institutions that coordinate global health action, but also the less formal norms, power relations, and financing mechanisms that determine who gets to address health problems, how priorities are set, and whose interests are served. As a subfield of global health, it sits at the intersection of public health, international relations, and political economy, asking questions that clinical medicine alone cannot answer: Why do some diseases attract massive global funding while others are neglected? Who has the authority to declare a public health emergency of international concern, and what does that authority actually accomplish? How do intellectual property rules shape access to medicines in poor countries?
Health has always crossed borders—epidemics do not respect sovereignty—but the modern governance of health is a relatively recent construction. For most of the nineteenth and early twentieth centuries, international health cooperation was limited to a narrow set of practical concerns: quarantine regulations, sanitation standards for shipping, and the collection of epidemiological statistics. These efforts were driven by the self-interest of trading nations seeking to protect their populations and commerce, not by any broader commitment to health as a global public good. The creation of the World Health Organization (WHO) in 1948 marked a shift toward a more ambitious vision, with a constitution declaring that "the enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being." Yet the WHO was designed as an intergovernmental agency with limited authority over its member states, and its mandate to coordinate rather than command has shaped the entire subsequent history of the field.
The central puzzle of global health governance is that the problems are global but the authority to address them remains overwhelmingly national. No world government exists to tax, regulate, or enforce health standards. Instead, governance emerges from a patchwork of institutions and arrangements: treaties, funding mechanisms, technical agencies, philanthropic foundations, advocacy networks, and private corporations. The subfield studies how this patchwork functions, where it fails, and how it might be reformed. Its stakes are enormous: the difference between life and death for millions of people, the distribution of the world's health resources, and the legitimacy of the international order itself.
The formal architecture of global health governance centers on the WHO, which serves as the primary intergovernmental forum for health. The WHO's most significant formal power is its authority under the International Health Regulations (IHR) to declare a Public Health Emergency of International Concern (PHEIC), a designation that triggers legally binding obligations for member states to report and respond to certain disease events. The IHR, first adopted in 1969 and substantially revised in 2005, represents one of the few binding legal instruments in global health. However, the WHO's budget is small relative to the scale of global health problems, and its effectiveness depends heavily on the willingness of powerful states to comply with its recommendations.
Around this formal core has grown a dense network of other actors. The World Bank has become a major health financier, treating health as a component of economic development. The Global Fund to Fight AIDS, Tuberculosis and Malaria, created in 2002, pioneered a new model of public-private partnership that pools donor contributions and disburses them through country-level mechanisms. Gavi, the Vaccine Alliance, similarly brings together governments, the vaccine industry, and philanthropic organizations to improve immunization coverage in poor countries. Private foundations, particularly the Bill and Melinda Gates Foundation, have become major funders and agenda-setters, often operating with fewer accountability constraints than public institutions. Non-governmental organizations such as Médecins Sans Frontières provide direct services and advocate for policy change, while also documenting failures of the system from within. Pharmaceutical companies, both as producers of essential medicines and as holders of intellectual property rights, are indispensable actors whose commercial interests frequently conflict with public health goals.
This proliferation of actors has generated a persistent tension between coordination and fragmentation. The WHO was designed to be the directing and coordinating authority on international health, but it now competes with well-funded initiatives that can set priorities through their spending decisions. The result is a system that is often described as a "regime complex"—not a single coherent order, but an overlapping set of institutions with partially aligned and partially conflicting mandates.
Scholars and practitioners approach global health governance from several distinct traditions, each with its own assumptions about how the system works and what should be changed.
The oldest and most straightforward approach focuses on the formal rules, organizations, and treaties that constitute global health governance. Scholars in this tradition analyze the mandates of international organizations, the content of legal instruments like the IHR and the Framework Convention on Tobacco Control, and the compliance of states with their obligations. The organizing assumption is that governance is primarily a matter of law and institutional design: if the right rules are in place and the right organizations have the authority to enforce them, health outcomes will improve. This approach has been influential in shaping reform proposals, such as calls to strengthen the WHO's emergency powers or to create new binding treaties for pandemic preparedness.
Its limits are equally clear. Formal rules often diverge sharply from actual practice. States may sign treaties they have no intention of fully implementing, and international organizations may lack the resources or political backing to enforce their mandates. The legal-institutional approach tends to understate the role of power, money, and informal influence in shaping what actually happens on the ground.
A second tradition, rooted in international political economy, examines how economic structures and power relations shape global health. Scholars in this vein analyze the role of intellectual property regimes in determining access to medicines, the influence of pharmaceutical companies on research priorities, the effects of trade agreements on health policy, and the ways in which global financing mechanisms reflect the interests of wealthy donors rather than the needs of poor countries. The organizing assumption is that health governance cannot be understood apart from the broader capitalist economy in which it is embedded.
This approach has been particularly influential in explaining why some health problems receive massive attention while others are neglected. The "10/90 gap"—the observation that only about ten percent of global health research funding is directed at the diseases that account for ninety percent of the global disease burden—is a classic political economy finding. The approach also illuminates why the global response to HIV/AIDS was so heavily shaped by activism and advocacy: affected communities had to organize politically to overcome the indifference of both governments and pharmaceutical companies.
The political economy tradition is sometimes criticized for being overly structural, leaving little room for agency or for the genuine improvements that have been achieved within the existing system. Its defenders respond that understanding the constraints is a necessary precondition for effective action.
A third tradition, drawing on critical theory and postcolonial studies, questions the very categories and assumptions on which global health governance rests. Scholars in this vein examine how the field reproduces colonial hierarchies, with wealthy countries and international institutions setting agendas for poor countries that are then expected to comply. They analyze the language of "capacity building" and "technical assistance" as forms of power that position the global South as perpetually deficient and dependent. They also examine how global health interventions can serve broader geopolitical interests, from Cold War-era population control programs to contemporary securitization of disease threats.
This approach has been influential in debates about the decolonization of global health, a movement that gained particular visibility during the COVID-19 pandemic. Critics argue that the field's governance structures remain dominated by Northern institutions and that genuine reform requires not just better coordination but a fundamental redistribution of authority and resources. The critical tradition is sometimes dismissed as insufficiently practical, but its insistence on examining who benefits from existing arrangements has forced the field to confront uncomfortable questions about its own legitimacy.
A fourth tradition, rooted in economics, conceptualizes health as a global public good—a benefit that is non-excludable and non-rivalrous, meaning that no one can be prevented from enjoying it and one person's enjoyment does not diminish another's. Disease control, antimicrobial resistance surveillance, and pandemic preparedness fit this definition: everyone benefits from the control of infectious diseases, regardless of who pays for it. The implication is that markets will underprovide these goods, because individual actors have little incentive to invest in benefits that others can enjoy for free. Governance, in this view, exists to correct this market failure through collective financing and coordinated action.
This approach has been highly influential in justifying international funding mechanisms and in framing global health as a matter of shared self-interest rather than charity. It has been criticized, however, for its tendency to prioritize those health issues that affect wealthy countries (such as pandemic threats) over those that primarily affect poor countries (such as neglected tropical diseases). The public goods framing can also obscure the fact that many health interventions are not public goods at all but private benefits that happen to be unequally distributed.
Global health governance as a distinct field of study emerged in the 1990s and early 2000s, driven by several converging developments. The HIV/AIDS pandemic exposed the inadequacy of existing international health arrangements and generated unprecedented mobilization of resources and activism. The creation of new financing mechanisms like the Global Fund and Gavi raised questions about how these new actors related to the WHO and to national governments. The 2005 revision of the International Health Regulations, prompted by the SARS outbreak of 2003, gave the WHO new powers and raised new questions about sovereignty and compliance. And the growing role of private philanthropy, particularly the Gates Foundation, challenged assumptions about the public character of global health governance.
The field's intellectual roots lie in international relations theory, particularly the study of international regimes and global governance more broadly. But it has also drawn heavily on public health, economics, law, and anthropology. This interdisciplinary character is both a strength and a source of ongoing tension: scholars from different disciplinary backgrounds often talk past each other, and there is no settled consensus on what the field's core questions should be.
The COVID-19 pandemic marked a watershed for the field, bringing global health governance to the center of public attention and exposing its weaknesses with unprecedented clarity. The WHO's declaration of a PHEIC in January 2020 was initially met with skepticism and was followed by widespread non-compliance with its recommendations. The global distribution of vaccines was dramatically unequal, with wealthy countries securing supplies for their own populations while poor countries waited. The pandemic also accelerated existing debates about the decolonization of global health and prompted a wave of proposals for institutional reform, including a new pandemic treaty and reforms to the WHO's financing and authority. Whether these reforms will materialize and whether they will address the underlying structural problems remains an open question.
The present landscape of global health governance is characterized by several durable features. First, the system remains fragmented and pluralistic, with no single actor able to coordinate the whole. The WHO retains formal authority but lacks the resources and political backing to exercise it effectively. The proliferation of vertical funds—initiatives focused on specific diseases rather than on strengthening health systems generally—has produced impressive results for some conditions while leaving broader health system weaknesses unaddressed.
Second, the role of private actors continues to expand. Philanthropic foundations, corporations, and public-private partnerships now play roles that would have been unthinkable a generation ago. This expansion has brought resources and innovation but also raised concerns about accountability, transparency, and the influence of private interests on public priorities.
Third, the field is increasingly contested politically. The rise of nationalist and populist movements in many countries has weakened support for multilateral institutions, including the WHO. The securitization of health—the framing of disease threats as security issues—has brought new attention and resources to global health but also risks subordinating health goals to geopolitical interests.
Fourth, the intellectual agenda of the field has broadened to include issues that were once considered domestic health policy. Non-communicable diseases, mental health, and the social determinants of health are now recognized as global governance concerns, even though they do not fit the traditional model of cross-border disease transmission. This expansion has made the field more relevant but also more diffuse, raising questions about what, if anything, holds it together.
Finally, the field is marked by persistent and unresolved debates about its own legitimacy. Who has the right to set global health priorities? Should decisions be made by technical experts, by governments, by affected communities, or by those who provide the money? These questions have no settled answers, and they are likely to become more pressing as the system continues to evolve. Global health governance, in this sense, is not a solved problem but an ongoing experiment in how to manage the health of a deeply unequal and interconnected world.